Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
Rationale Escitalopram is a widely used antidepressant for the treatment of patients with major depression. It is the pure S-enantiomer of racemic citalopram. Several clinical trials and meta-analyses indicate that escitalopram is quantitatively more efficacious than many other antidepressants with a faster onset of action.Objective This paper reviews current knowledge about the mechanism of action of escitalopram.Results The primary target for escitalopram is the serotonin transporter (SERT), which is responsible for serotonin (or 5-hydroxytryptamine [5-HT]) reuptake at the terminals and cell bodies of serotonergic neurons. Escitalopram and selective serotonin reuptake inhibitors bind with high affinity to the 5-HT binding site (orthosteric site) on the transporter. This leads to antidepressant effects by increasing extracellular 5-HT levels which enhance 5-HT neurotransmission. SERT also has one or more allosteric sites, binding to which modulates activity at the orthosteric binding site but does not directly affect 5-HT reuptake by the transporter. In vitro studies have shown that through allosteric binding, escitalopram decreases its own dissociation rate from the orthosteric site on the SERT. R-citalopram, the nontherapeutic enantiomer in citalopram, is also an allosteric modulator of SERT but can inhibit the actions of escitalopram by interfering negatively with its binding. Both nonclinical studies and some clinical investigations have demonstrated the cellular, neurochemical, neuroadaptive, and neuroplastic changes induced by escitalopram with acute and chronic administration.Conclusions The findings from binding, neurochemical, and neurophysiological studies may provide a mechanistic rationale for the clinical difference observed with escitalopram compared to other antidepressant therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Escitalopram is considered the most selective of the SSRIs [50], but could have important off-target effects according to a recent study: An allosteric binding site at the tropomyosin receptor kinase B (Trk-B) was identified as a low-affinity target of drugs representing several classes of antidepressants, including the SSRIs [51].”
From Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial (2023) · cites this paper as [50]
Citations
Cites
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162 · cited 1×
“The short (S) allele lacks this 44 base pair insertion and has a 3-fold lower 5-HT uptake function in lymphoblasts compared to the L allele, due to reduced transcriptional efficiency (Lesch et al. 1996).”
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 2×
“A single dose of ketamine, an anesthetic with a very fast onset (in hours) and strong antidepressant efficacy (Berman et al. 2000; Zarate et al. 2006), can induce sustained increases in synaptic synapsin I, GluR1, and PSD95 in the rat prefrontal cortex, probably mediated through AMPA and mTOR…”
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“…an anesthetic with a very fast onset (in hours) and strong antidepressant efficacy (Berman et al. 2000; Zarate et al. 2006), can induce sustained increases in synaptic synapsin I, GluR1, and PSD95 in the rat prefrontal cortex, probably mediated through AMPA and mTOR signaling (Li et al. 2010).”
Ollinger, J. M., & Fessler, J. A. (1997) · IEEE Signal Processing Magazine · doi:10.1109/79.560323 · Cited by 1,167
Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter
Owens, M. J., & Nemeroff, C. B. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.2.288 · Cited by 929
Zhou, L., & Zhu, D.-Y. (2009) · Nitric Oxide · doi:10.1016/j.niox.2009.03.001 · Cited by 663 · cited 2×
“…example of SIPs is the neuronal nitric oxide synthase (nNOS), which is widely expressed in the brain with functional roles in learning, memory, and neurogenesis and has been associated with various CNS disorders such as depression, Parkinson’s disease, and Alzheimer’s disease (Zhou and Zhu 2009).”
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551 · cited 2×
“provide therapeutic benefits by affecting more than one neurotransmitter system and thereby via different points of intervention modulate downstream events that are needed for the antidepressant activity (Millan 2006; Wong et al. 2008).”
Lucassen, P. J., Meerlo, P., Naylor, A. S., van Dam, A. M., Dayer, A. G., Fuchs, E., Oomen, C. A., & Czéh, B. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.08.003 · Cited by 449 · cited 2×
“In addition to antidepressants, it is now known that many compounds can induce neurogenesis, and its functional impact and contribution to the etiology of depression and the treatment mechanism remains unclear (Lucassen et al. 2010).”
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters
Singh, S. K., Yamashita, A., & Gouaux, E. (2007) · Nature · doi:10.1038/nature06038 · Cited by 413 · cited 2×
“Co-crystal structures of the tricyclic antidepressants clomipramine and desipramine with LeuT have provided models for the understanding of inhibitor binding to the SERT (Singh et al. 2007; Zhou et al. 2007).”
Research works printed but not linked: 1
- Loland CJ, Plenge P, Shi L, Zhang P, Javitch JA, Newman AH, Weinstein H, Gether U (2010) Mapping of the allosteric binding site in the serotonin transporter. Basic Clin Pharmacol Toxicol 107:116–117
Cited by
Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats
Mørk, A., Montezinho, L. P., Miller, S., Trippodi-Murphy, C., Plath, N., Li, Y., Gulinello, M., & Sanchez, C. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.01.019 · Cited by 298
Self-citationA comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
Serotonergic Drugs for Depression and Beyond
M. Stahl, S., Lee-Zimmerman, C., Cartwright, S., & Ann Morrissette, D. (2013) · Current Drug Targets · doi:10.2174/1389450111314050007 · Cited by 272
Phytochemistry and pharmacology of anti-depressant medicinal plants: A review
Martins, J., & Brijesh, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.044 · Cited by 167
Brain activity during cocaine craving and gambling urges: an fMRI study
Kober, H., Lacadie, C. M., Wexler, B. E., Malison, R. T., Sinha, R., & Potenza, M. N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.193 · Cited by 160
Metadata
- Authors
- Zhong, H., Haddjeri, N., & Sánchez, C.
- Affiliations
- Lyon 1 Université (FR)
- Lundbeck (United States) (US)
- Corresponding author
- Zhong, Huailing
- Venue
- Psychopharmacology
- Published
- 2011-09-08
- Volume
- 219
- Issue
- 1
- Pages
- 1-13
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2031385069
- Cited by
- 105
- References
- 111
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 8 · 2023: 7 · 2022: 8 · 2021: 8 · 2020: 4 · 2019: 4 · 2018: 9 · 2017: 4 · 2016: 10 · 2015: 10 · 2014: 9 · 2013: 7 · 2012: 3
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- escitalopram, serotonin transporter, allosteric modulation, orthosteric binding site, selective serotonin reuptake inhibitors, major depressive disorder, antidepressant mechanism, serotonergic neurotransmission, neuroplasticity, neural adaptation
- MeSH terms
- Allosteric Regulation, Animals, Depressive Disorder, Humans, Citalopram, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action. https://app.cochat.ai/papers/10.1007/s00213-011-2463-5
- The paper
- Zhong, H., Haddjeri, N., & Sánchez, C. (2012). Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action. Psychopharmacology. https://doi.org/10.1007/s00213-011-2463-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.